Cure My Disease

Don't miss your cure!

 Log in / Sign up

Off-the-Shelf immune cells take on Hard-to-Treat lymphomas

NCT ID NCT04848064

Recruiting now Disease control Sponsor: John Reneau Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial is testing a combination of donor natural killer (NK) cells and the drug mogamulizumab in 12 patients with relapsed or refractory cutaneous T-cell lymphoma or adult T-cell leukemia/lymphoma. The NK cells are grown in the lab and given 'off the shelf' to boost the immune system's ability to attack cancer, while mogamulizumab helps flag cancer cells for destruction. The main goal is to find the safest dose and see if the combination can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
natural killer (NK) cells from healthy donors, combined with mogamulizumab (a monoclonal antibody)
What this could lead to
If it works, this could point toward a new treatment option for patients with T-cell lymphomas that have stopped responding to standard therapies.
What could go wrong
This is a very early phase I trial with only 12 participants, so it is primarily testing safety and dosing. The combination may not work or could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adult T-cell leukemia/lymphoma Precursor T-Cell Lymphoblastic Leukemia-Lymphoma primary cutaneous T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA REFRACTORY ADULT T-CELL LEUKEMIA/LYMPHOMA REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.